Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Gastric/GEJ Cancer
What factors (age, PS) do you consider to avoid using FLOT in the perioperative treatment of gastric and esophageal cancers?
Related Questions
For metastatic cholangiocarcinoma that has progressed on first line chemotherapy and immunotherapy, that is HER2 3+, which HER2 regimen is preferred, TDxD, Zanidatamab or tucatinib/trastuzumab?
Would you offer zolbetuximab in a non-Asian population?
How are you sequencing immunotherapy with zolbetuximab in locally advanced/metastatic GEJ cancer when CPS >5 and Claudin 18.2+ (>75%)?
Would you offer zolbetuximab + chemotherapy in a presumed metastatic duodenal bulb adenocarcinoma with 80% Claudin18.2 expression?
How would you treat newly diagnosed stage IV GEJ adenocarcinoma with both Claudin 18.2 and HER2 (3+ via IHC) overexpression?
What are your top takeaways from ASCO GI 2025?
Would you offer surgery for an MSI-H pancreatic adenocarcinoma who had deep response to pembrolizumab?
What are your first line treatment choices for metastatic combined HCC/Cholangiocarcinoma?
Which patients with localized esophageal adenocarcinoma, if any, would you offer nivolumab after lack of pCR to neoadjuvant FLOT?
Do you always biopsy suspicious liver lesions if you have a biopsy from the pancreatic mass showing PDAC?
